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Abstract Intracellular CD95/Fas-signaling pathways have not
been investigated in melanoma yet. Two different CD95
receptor-induced apoptotic pathways are presently known in
other cell types: (i) direct activation of caspase-8 and (ii)
induction of ceramide-mediated mitochondrial activation, both
leading to subsequent caspase-3 activation. In the present study,
five of 11 melanoma cell populations were shown to release
cytochrome c from mitochondria, which activates caspase-3 and
finally results in DNA fragmentation upon treatment with the
agonistic monoclonal antibody CH-11. In contrast, this apoptotic
pathway was not activated in the remaining six melanoma cell
populations. Interestingly, the susceptibility of melanoma cells to
CD95L/FasL-triggered cell death was clearly correlated with N-
acetylsphingosine-mediated apoptosis. Our results are in line
with a defect upstream of mitochondrial cytochrome c release in
resistant cells.
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1. Introduction
APO-1/Fas, now called CD95, was the ¢rst member of the
tumor necrosis factor (TNF) receptor subfamily named death
receptors, described in terms of its function to trigger apopto-
sis upon binding of its ligand (CD95/Fas Ligand (CD95L/
FasL)) or speci¢c agonistic antibodies [1]. Stimulation of
CD95 results in oligomerization of the receptors and recruit-
ment of two key signaling proteins, adapter protein-FADD
(Fas-associated death domain, also called MORT-1) and cas-
pase-8 [2], forming a death inducing signaling complex (DISC)
[3]. Caspase-8 activation is followed by caspase-3 activation
which seems to be the most important e¡ector in this apo-
ptotic pathway [4]. Besides the FADD/caspase-8 pathway, a
novel CD95-mediated apoptotic pathway with involvement
of mitochondria has been identi¢ed and its pivotal role as
orchestrator of apoptosis has been ¢rmly established [5]. Dur-
ing apoptosis in vitro and in vivo cytochrome c is released
from mitochondria, and cytosolic cytochrome c forms an es-
sential part of the vertebrate ‘apoptosome’, composed of cy-
tochrome c, apoptotic protease activating factor-1 (Apaf-1)
and procaspase-9 [6]. This results in activation of caspase-9,
which then processes caspase-3, whereby the cell passes the
threshold of no return. Cytochrome c release can be inhibited
by anti-apoptotic members of proteins of the B-cell lymphoma
proto-oncogene 2 (bcl-2) family which are described as the
e¡ectors of this apoptotic pathway [7]. Another pathway im-
plicated in death receptor-mediated apoptosis involves the
generation of ceramide by hydrolysis of the membrane sphin-
gophospholipid sphingomyelin [8]. Ceramide is a signaling
molecule involved in cellular responses to a variety of apo-
ptotic stimuli [9]. It is produced upon activation of sphingo-
myelinases (SMases) or via de novo synthesis by ceramide
synthase [10,11].
In experiments overexpressing bcl-2, ceramide-stimulated
cells showed a signi¢cant decrease of cell death, thereby re-
vealing the importance of mitochondrial function in ceramide-
mediated apoptosis [12]. In U-937 cells, ceramide increase was
shown after treatment with agonistic anti-Fas antibodies and
exogenous addition of cell-permeable N-acetylsphingosine
(C2-ceramide) induced apoptosis in various malignant cells
[13]. Dysregulation of the Fas-signaling system was shown
to contribute to formation and growth of neoplasia including
malignant melanoma. Melanoma is a tumor showing an in-
creasing incidence and aggressive biological behavior. Mela-
noma cells defy endogenous apoptosis and resist very e¡ec-
tively to di¡erent physiological mechanisms triggering the
apoptotic cascade and causing cell death, such as CD95/
CD95L [14]. However, the role of ceramide-mediated apopto-
sis for the development of CD95/CD95L resistance in mela-
noma cells has not been investigated yet.
In the present study, we determined the susceptibility of
nine melanoma cell lines and two primary cultures from mel-
anoma lesions to apoptosis mediated by CD95 agonistic anti-
bodies and truncated ceramides. We demonstrate here, that
the susceptibility to these apoptotic stimuli was in correlation
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with a defect in cytochrome c release and the resulting loss of
caspase-3 activation.
2. Materials and methods
2.1. Melanoma cells and reagents
Two melanoma cell populations (M186, M221) were obtained from
patients with histologically con¢rmed metastatic melanoma by surgi-
cal intervention. Four out of nine established human melanoma cell
lines used in this study originated from primary tumors: A-375 [15],
Bro [16], JPC-298 [17], Mel-HO [18], and ¢ve cell lines originated
from metastases: Mel-2A [19], MeWo [20], SK-Mel-13, SK-MEL-
23, SK-Mel-28 [21]. All melanoma cell lines were grown in DMEM
supplemented with 10% fetal bovine serum and 100 U/ml penicillin
and 100 Wg/ml streptomycin. Agonistic anti-CD95 monoclonal anti-
bodies CH-11 (Chemicon, Hofheim, Germany) were used at a ¢nal
concentration of 1 Wg/ml. C2-ceramide and C8-ceramide were pur-
chased from Alexis (Gruenberg, Germany) and dissolved in ethanol
to give a 10 mM stock solution.
2.2. Reverse transcription-polymerase chain reaction (RT-PCR)
detection
Total RNA was isolated according to the manufacturer’s protocol
with a commercially available kit (Quiagen, Hilden, Germany). The
RNAs were converted into cDNA with the kit from Gibco BRL
(Karslruhe, Germany) according to their instructions. PCR was per-
formed with gene-speci¢c, intron-spanning primers at a ¢nal concen-
tration of 1 mM dNTPs, 10 WM each of the primers and 2.5 Units (U)
of Taq DNA polymerase (Perkin Elmer, Heidelberg, Germany) in a
total volume of 50 Wl. Thermal cycling was carried out as follows: one
cycle of 94‡C for 1 min followed by 30 cycles of 94‡C for 30 s, 60‡C
for 1 min, 72‡C for 1 min and an additional extension period at 72‡C
for 5 min. An aliquot of 20 Wl of each reaction was separated by
electrophoresis using a 2% agarose gel and visualized with ethidium
bromide.
The primer pairs were purchased from TibMolbiol (Berlin, Ger-
many). Sequences are available under http://www.medizin.fu-berlin.
de/ceramide/protocols/primers.html.
2.3. Cytotoxicity assays
Cytotoxicity was determined with the cytotoxicity detection kit (lac-
tate dehydrogenase (LDH)) from Roche Diagnostics (Mannheim,
Germany) exactly as described elsewhere [22]. Extinction values of
control cells were set as 100% and the rate of LDH release from
treated cells was calculated as % of control.
2.4. Determination of apoptosis
Con£uent cells in 24-well plates were treated with the respective
agents or control vehicle in DMEM. After 12 h of incubation, cell
death was measured in a photometric enzyme-immunoassay for the
qualitative and quantitative in vitro determination of cytoplasmic his-
tone-associated DNA fragments (mono- and oligonucleosomes) with
the commercially available kit ‘Cell death detection ELISAPLUS’ from
Roche Diagnostics (Mannheim, Germany), exactly as described else-
where [22]. Extinction values of control cells were set as 100% and the
rate of LDH release from treated cells was calculated as % of control.
2.5. Radiolabelling of cells and sphingomyelin quantitation
Cells were labelled with choline as described previously [23]. Me-
dium was removed and pulse medium (DMEM containing 3.7U104
Bq/ml [methyl-3H]choline) was added. After incubation for 72 h, cells
were washed twice with phosphate-bu¡ered saline (PBS) and then
treated with 1 Wg/ml CH-11 antibodies in DMEM. After incubation
for 8 and 10 h, cells were harvested in 400 Wl ice-cold PBS. After
freeze-drying of the cells, lipids were extracted as described [24]. Total
lipid extracts were dried under a stream of nitrogen and stored at
320‡C. Sphingomyelin was quanti¢ed using bacterial SMase to re-
lease [3H]phosphocholine as described recently [25]. The radioactivity
in control samples was set as 100%. Subsequently, sphingomyelin in
the samples of CH-11 treated cells was calculated as percent of con-
trol.
2.6. Preparation of cytosolic extracts and mitochondria
Mitochondrial and cytosolic extracts were prepared according to a
method described previously [26]. After incubation with the respective
substances, cells were harvested in PBS, equilibrated in hypotonic
bu¡er (20 mM HEPES (pH 7.4), 10 mM KCl, 2 mM MgCl2, 1 mM
EDTA) and centrifuged at 300Ug for 5 min. The resulting pellet
was then dissolved in hypotonic bu¡er with addition of PMSF (f.c.
0.1 mM) and incubated on ice for 15 min. Cells were homogenized by
passing the cells through a syringe (G 20) approximately 20 times. The
membranes were isolated by two-fold centrifugation at 10 000Ug at
4‡C for 10 min and the supernatant of the second centrifugation was
used as cytosolic extract. The resulting mitochondrial pellets were
solubilized in lysis bu¡er (1% Triton X-100, 50 mM Tris, pH 7.4,
150 mM NaCl containing 1 WM leupeptin, 1 WM pepstatin and 100
WM phenylmethyl sulfonyl£uoride) and together with the clear super-
natants frozen at 380‡C. Western blot analyses with cytosolic and
mitochondrial extracts were performed as described below and con-
ducted with mouse anti-cytochrome c antibodies (Pharmingen, Ham-
burg, Germany) with a 1:1000 dilution. The second horseradish per-
oxidase-coupled anti-mouse antibody (Dako, Hamburg, Germany)
was used at a 1:10 000 dilution.
2.7. Determination of caspase-3 processing in intact cells (in vivo)
After treatment of melanoma cells (A375, M186, Mel2A, M221)
with 1 Wg/ml anti-CD95 antibodies for 6 h or 30 WM C2-ceramide
for 4 h, cells were washed with PBS and lysed with lysis bu¡er as
described above. Then, 45 Wg of cytosolic protein were separated on a
15% SDS^polyacrylamide gel electrophoresis (PAGE) and blotted to
nitrocellulose membrane as described [27]. Membranes were blocked
for 1 h with 3% non-fat dry milk in PBS containing 0.25% Tween-20
and then incubated with rabbit polyclonal antibodies to caspase-3
(Pharmingen, Hamburg, Germany) in 1:2000 dilution. The blots
were counterstained with goat anti-rabbit IgG conjugated with horse-
radish peroxidase (Promega, Mannheim, Germany) in 1:4500 dilution
for 1 h. The immunoreactive bands were visualized by incubation of
the membrane with enhanced chemiluminescence reagent ECL from
Pierce (Rockford, IL, USA). Interblot reproducibility of identical
samples was checked and detection of caspase-3, as determined by
Western blot and subsequent videodensitometry, showed a coe⁄cient
of variation of 8.3%. The detection limit for the 17 kDa cleavage
product of caspase-3 which represents the active form of the enzyme
was below 0.1 mU (data not shown).
2.8. Determination of caspase-3 and caspase-9 activation in cell-free
extracts
To measure caspase activation in vitro, cytosolic extracts of mela-
noma cells were prepared as described above. To in vitro activate
caspase-3 and caspase-9, 10 WM cytochrome c (Sigma, Munich, Ger-
many), 1 mM dATP and 1 mM dithiothreitol were added to cytosolic
extracts. After incubation for 30 min at 30‡C, 10 Wl of this enzyme
extract, 2 Wl caspase-3 substrate Ac-Asp Glu-Val-Asp-pNA (Ac-
DEVD-pNA; Calbiochem, Bad Soden, Germany) or caspase-9-sub-
strate Ac-LEHD-pNA (Chemicon, Hofheim, Germany) and 90 Wl of
bu¡er B (50 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.1%
CHAPS and 10% saccharose) were incubated for up to 90 min at
37‡C. Photometrical measurements were performed at 405 nm in an
ELISA-reader. As negative controls, cellular extracts were incubated
in the absence of cytochrome c and dATP, and caspase-3 and caspase-
9 activities were determined as described above. One unit of enzyme
activity is de¢ned as Wmol Ac-DEVD-pNA or Wmol Ac-LEHD-pNA
cleaved per min.
3. Results
3.1. Susceptibility of melanoma cells to CD95-mediated
apoptosis by CH-11 monoclonal antibody (mAb)
In preliminary experiments, 1 Wg/ml agonistic anti-CD95
mAb CH-11 was shown to be the most e¡ective concentration
for apoptosis induction (data not shown). A panel of melano-
ma cell cultures was treated for 12 h with CH-11 and apo-
ptosis was determined morphologically by observation under
light microscope and measured photometrically using an en-
zyme immunoassay for determination of cytoplasmic histone-
associated DNA fragments. As listed in Table 1, CH-11-in-
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duced apoptosis occurred in four melanoma cell lines (MelHo,
Bro, SKMel 13 and A375) and one primary culture (M186).
In contrast, JPC298 cells, MEWO cells, SkMel28 cells,
SkMel23 cells and Mel2A cells remained completely resistant
to CH-11 stimulation (Table 1) even after prolonged incuba-
tion times of 36 h (data not shown).
3.2. Determination of the e¡ectors of the CD95 signaling
pathway in di¡erent melanoma cells
In order to investigate the role of key e¡ectors in the CD95
signaling pathway, we screened the expression of CD95-asso-
ciated genes with RT-PCR in the panel of nine melanoma cell
lines and two primary cultures from melanoma lesions. To
test the relative quantity of cDNAs, each of them was
screened for the housekeeping gene Ribo S9 and for the ab-
sence of genomic DNA contamination. For all screened genes
intron spanning primers were used. The colon adenocarcino-
ma cell line, SW 480, expressing CD95L mRNA [28] was
taken as a positive control. None of the 11 melanoma cell
lines expressed CD95L mRNA and this result was con¢rmed
with Northern blot analysis, where no expression of CD95L-
mRNA could be detected (data not shown). On the other
hand, signi¢cant expression levels of CD95, adapter protein
FADD, caspase-8 and caspase-3 mRNA were found in resist-
ant as well as sensitive melanoma cells.
In another set of RT-PCR experiments, we compared the
gene expression of bcl-2, bcl-xL, bax and FLIP (FLICE-inhib-
itory protein) in resistant and sensitive melanoma cell lines,
but no di¡erences in gene expression on mRNA level could be
detected.
3.3. Induction of sphingomyelin hydrolysis by activation of the
CD95 signaling pathway in melanoma cells
CD95 ligand induces apoptosis via activation of the sphin-
gomyelin cycle in U937 cells [29]. Triggering of the CD95 cell-
surface receptor with 1 Wg/ml CH-11 induced hydrolysis of
approximately 30% of the total sphingomyelin in both sensi-
tive and resistant melanoma cells (Fig. 1). These results ex-
Table 1
Susceptibility of melanoma cell populations to CH-11 mAb and C2-
ceramide
Cell populations CH-11 C2-ceramide
JPC298 3 3
MEWO 3 3
A375 +++ +++
SkMel28 3 3
BRO + +
M186 ++ ++
M221 3 3
MelHo ++ ++
SkMel23 3 3
SkMel13 + +
Mel2A 3 3
The panel of melanoma cell populations was treated for 12 h with
1 Wg/ml of agonistic anti-CD95 CH-11 mAb. The same cell popula-
tions were treated with exogenously applied 30 WM cell-permeable
C2-ceramide for 6 h. Apoptosis was measured photometrically using
an enzyme immunoassay for determination of cytoplasmic histone-
associated DNA fragments (for details, see Section 2). Results of
apoptosis detection: 3, resistant; +, weak; ++, intermediate; +++,
strong sensitivity.
Fig. 1. CH-11 induces sphingomyelin hydrolysis in both sensitive
and resistant melanoma cells. Sensitive (A375, M186) and resistant
(Mel-2A, M221) melanoma cells which had been previously labelled
for 72 h with [3H]choline were washed with PBS and stimulated
with CH-11 for 8 and 10 h. Subsequently, cells were washed with
ice-cold PBS and harvested in PBS. Cellular lipids were extracted
according to Bligh and Dyer and sphingomyelin hydrolysis was de-
termined as described in Section 2. Values are given as percent of
control þ S.D. (n = 3).
Fig. 2. Cytochrome c is released upon stimulation with CH-11 and
C2-ceramide in sensitive melanoma cells. For the detection of cyto-
chrome c release, cells were harvested after stimulation with CH-11
for 6 h and C2-ceramide for 4 h and cytosolic and mitochondrial
extracts were prepared according to the protocol mentioned in Sec-
tion 2. Western blot was performed with anti-human cytochrome c
antibodies. The experiment was repeated twice and similar results
were obtained.
Fig. 3. Activation of caspase-3 after stimulation with CH-11 and
C2-ceramide in sensitive (A375, M185) and resistant (SkMel23,
M221) cells. Cells were stimulated with 1 Wg/ml CH-11 mAb and
C2-ceramide for 6 and 4 h, respectively. Then, protein extracts were
prepared and separated by SDS^PAGE. Western blot was carried
out as described in Section 2. Arrows at the right margin indicate
the migration positions of procaspase-3 (32 kDa) and its cleavage
products (17 and 20 kDa) recognized by the anti-human caspase-3
Ab used in the immunoblot. The experiment was repeated twice and
similar results were obtained.
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clude the possibility of a defect at the level of SMase in re-
sistant cells.
3.4. Susceptibility of melanoma cells to C2-ceramide
In order to investigate the possible role of ceramide in our
system, melanoma cell lines were treated with 30 WM C2-cer-
amide for 6 h. Unspeci¢c cytotoxic e¡ects of C2-ceramide on
melanoma cells were determined after 2 h of incubation by
measurement of the release of LDH activity into cell culture
supernatants. It was shown that 30 WM C2-ceramide did not
cause necrotic cell death in melanoma cells (data not shown).
On the other hand, C2-ceramide was able to induce apoptosis
in four melanoma cell lines (MelHo, Bro, SKMel 13 and
A375) and one primary culture (M186) with di¡erent sensitiv-
ity among these cells (Table 1). The other melanoma popula-
tions tested (JPC298, MEWO, SkMel28, SkMel23, Mel2A)
remained completely resistant to 30 WM C2-ceramide (Table
1) even after longer incubation periods up to 36 h (data not
shown). The same results were obtained with C8-ceramide
(data not shown). Thus, our observations might be also rep-
Fig. 4. Caspase activation in vitro. Cytosolic extracts were incubated with 10 WM cytochrome c, 1 mM dATP and 1 mM dithiothreitol for 30
min in hypotonic bu¡er as described in Section 2. Then, caspase-9 (A) and caspase-3 (B) activity were measured at 37‡C using Ac-LEHD-pNA
and Ac-DEVD pNA, respectively. Photometrical measurements were done at 405 nm in an ELISA-reader. As negative controls, cell extracts
which were likewise incubated in the absence of cytochrome c and dATP were used. The caspase enzyme activities were determined as maxi-
mum initial velocity Vmax. Data represent the mean of two determinations and are given as U/Wg protein. The experiment was repeated twice
and similar results were obtained.
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resentative for long chain ceramides, as has been reasoned
recently [30]. As listed in Table 1, there is a complete corre-
lation between the sensitivity of melanoma cells towards C2-
ceramide and their susceptibility towards CH-11 treatment.
This was found to be highly signi¢cant (P = 0.0022, Fisher’s
exact test).
3.5. Cytochrome c release occurs only in CD95/C2-ceramide
sensitive cells
It has been shown recently that ceramide acts upstream of
mitochondria and induces cytochrome c release from these
organelles [31]. Thus, cytosolic extracts of melanoma cells
were prepared and cytochrome c release after stimulation
was determined by Western blot analysis. Mitochondrial ex-
tracts of the di¡erent cell lines were included as positive con-
trols. As shown in Fig. 2, stimulation of the sensitive mela-
noma cells A375 and M186 with CH-11 and C2-ceramide
provoked the translocation of cytochrome c into the cytosol.
In contrast, in the resistant cells Mel-2A and M221 cyto-
chrome c release was absent after 6 h of incubation with
CH-11 and after 4 h of incubation with C2-ceramide. Even
after treatment with CH-11 for 8 and 10 h or C2-ceramide for
6 and 8 h, cytochrome c was not detectable in cytosolic ex-
tracts of resistant cells (data not shown).
3.6. Activation of caspase-3 in melanoma cells after stimulation
with anti-CD95 mAb and C2-ceramide
To further analyze the downstream mitochondrial pathway
in both cell types, caspase-3 processing and activation was
analyzed by Western blot using anti-caspase-3 antibody which
detects the proenzyme and cleaved forms of the enzyme. After
6 h of treatment with 1 Wg/ml CH-11 we detected the active 17
kDa cleavage form of caspase-3 in the sensitive cells A375 and
M186 (Fig. 3). In accordance with their failure to release
cytochrome c, the resistant cells Mel-2A and M221 did not
show any cleavage product of caspase-3 indicating that cas-
pase-3 was not active. Similar experiments were carried out
after C2-ceramide treatment for 4 h. The two sensitive mela-
noma cell populations showed the active cleavage form, while
the two resistant populations did not show any caspase-3
activation (Fig. 3) even after 8, 10 and 12 h of treatment
(data not shown).
In order to exclude a defect in the process of caspase-acti-
vation in resistant melanoma cells, cytochrome c and dATP
were directly added to cytosolic extracts of the respective cell
line. After incubation for 1 h at 30‡C, caspase-3 and caspase-9
activities were measured in a colorimetric assay. All CD95-
and C2-ceramide sensitive (A375, Mel-HO, Bro, M186, SK-
Mel-13) as well as the resistant melanoma cells (SK-Mel-23,
SK-Mel-28, M221, JPC, MeWo, Mel-2A) showed activation
of caspase-9 (Fig. 4A) and caspase-3 (Fig. 4B).
4. Discussion
Melanoma cells have been shown to defy CD95-mediated
apoptosis in vitro, despite the CD95 expression [14]. This fact
suggests a possible correlation with the situation in vivo,
where CD95-positive melanoma cells escape the immune re-
sponse of the CD95L-positive tumor in¢ltrating T-lympho-
cytes.
In the present study, we tried to elucidate the mechanisms
underlying the resistance to CD95-mediated apoptosis in hu-
man melanoma cells. For this, nine melanoma cell lines and
two primary melanoma cultures from melanoma lesions were
tested for their susceptibility to CD95-mediated apoptosis. We
found that four melanoma cell cultures and one primary cul-
ture were CD95 sensitive and six melanoma cell lines includ-
ing one primary culture were resistant. It has recently been
shown that the CD95 expression level does not correlate with
the sensitivity to CD95-induced apoptosis [32]. Furthermore,
CD95 mutation in melanoma is a rare event occurring in only
6.8% of primary cultures from melanoma patients and should
be of minor importance for development of CD95 resistance
[33]. Therefore, we focussed our interest on death signaling
downstream of the death receptor. We reasoned that the acti-
vation state and resistance to apoptosis might be attributed to
absence of key e¡ectors in CD95 signaling pathways. How-
ever, there was no di¡erence in gene expression pattern in-
cluding e¡ectors, inhibitors and regulators of CD95-induced
cell death in any of the cell populations determined by RT-
PCR. The ¢ndings that the same panel of CD95 sensitive
melanoma cells was also susceptible to truncated ceramides
whereas the remaining melanoma cell populations were resist-
ant for both stimuli led us to search for the blockade in the
joint section of CD95/C2-ceramide apoptotic pathways, down-
stream of FADD.
Only the stimulation of sensitive melanoma cells in vivo
with CH-11 released cytochrome c into the cytosol and led
to activation of caspase-3, while resistant melanoma cells
failed to translocate cytochrome c and to activate the down-
stream execution process. This points out the central role of
mitochondria as key regulators in susceptibility to CD95L and
C2-ceramide in melanoma cells and reveals that the resistance
of melanoma cells to apoptotic stimuli such as CD95L and
C2-ceramide is caused by a dysregulation of mitochondrial
executional functions. The key regulators of cytochrome c
release from mitochondria are represented by di¡erent mem-
bers of the bcl-2 protein family. Some of the members of the
bcl-2 family, e.g. bad and bax, are promoters, whereas others,
e.g. bcl-2 and bcl-xL, are inhibitors of apoptosis [34]. It seems
that the release of cytochrome c and other apoptogenic pro-
teins is determined by the relative amounts of apoptosis-pro-
moting and apoptosis-inhibiting bcl-2 proteins in the outer
membrane of the mitochondrion. Inappropriate overexpres-
sion of bcl-2 plays a role in promoting various types of tu-
mors, e.g. human follicular B cell lymphoma, and disbalance
in the bcl-2/bax ratio has been shown to be a determining
factor for breast cancer [35^37]. However, bcl-2 expression
is a common ¢nding in melanocytic lesions regardless of their
biological behavior and the progression of malignant melano-
ma does not depend on the high expression of bcl-2 [38,39].
A discussion about the role of ceramide in the CD95 signal-
ing pathway has been raised [40,41] and it is still a matter of
debate whether ceramide is functionally involved in the prop-
agation of CD95 death signal or just represents a secondary
modulatory pathway. In this context our results, showing that
increasing intracellular ceramide levels via exogenous addition
of truncated ceramides speci¢cally induced apoptosis in CD95
sensitive cells, support the signi¢cant role of ceramide in the
CD95 apoptotic pathway in human melanoma cells.
The above discussed cell line data are corroborated by the
results obtained from the sensitive and resistant primary cul-
tures. Thus, the di¡erent susceptibility of melanoma popula-
tions in vitro may re£ect the situation in vivo, where various
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malignant melanomas show di¡erences in their aggressive bio-
logical behavior. Furthermore, malignant melanomas also
show diverse sensitivity to apoptotic stimuli, e.g. to CD95L
expressed on tumor-in¢ltrating lymphocytes, Q-irradiation or
chemo- and immunotherapeutics. Taken together, our data
demonstrate for the ¢rst time that this diversity may be re-
lated to their potential to release cytochrome c from mito-
chondria in these cells.
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